View Older Stories View More Recent Stories

May 30, 2023 09:00AM Viatris Named to USA Today's Inaugural List of America's Climate Leaders 2023
May 25, 2023 02:22PM ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – VTRS
May 22, 2023 07:40AM Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year
May 22, 2023 06:30AM Viatris Inc (VTRS) Appoints Leo Groothuis to its Board
May 22, 2023 06:30AM Viatris Announces Appointment of Leo Groothuis to Company's Board of Directors
May 17, 2023 06:59AM Viatris to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
May 16, 2023 02:00PM Viatris Publishes Sustainability Report Showcasing 2022 Progress on Building Sustainable Access to Medicine
May 16, 2023 09:00AM Viatris Publishes Sustainability Report Showcasing 2022 Progress on Building Sustainable Access to Medicine
May 8, 2023 06:59AM Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
Apr 24, 2023 07:00AM Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting
Apr 12, 2023 09:00AM Viatris to Report First Quarter 2023 Financial Results on May 8, 2023
Apr 6, 2023 07:00AM NCD Academy Launches New Health Equity and Social Determinants of Health Course
Mar 31, 2023 03:47PM Viatris (VTRS) Wins Summary Judgment in New York Securities Class Action
Mar 31, 2023 03:46PM Viatris Wins Summary Judgment in New York Securities Class Action
Feb 27, 2023 07:45AM Viatris Inc (VTRS) Appoints Scott A. Smith as Next CEO
Feb 27, 2023 07:45AM Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023
Feb 27, 2023 06:00AM Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance
Feb 15, 2023 11:15AM Viatris to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
Jan 3, 2023 09:00AM Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division
Dec 29, 2022 04:05PM Viatris Inc (VTRS) Appoints Scott A. Smith and Elisha W. Finney to its Board
Dec 29, 2022 04:05PM Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors
Dec 23, 2022 06:59AM Viatris Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference
Dec 14, 2022 09:05AM Viatris Announces Donations Totaling $1 Million to Provide Aid Supporting Access to Healthcare, Food Security and Water Stewardship
Dec 14, 2022 09:00AM Viatris Announces Approval of Emissions Reduction Targets by the Science Based Target initiative (SBTi)
Nov 29, 2022 08:00AM Viatris Completes Biosimilars Transaction with Biocon Biologics
Nov 18, 2022 06:59AM Viatris Named U.S. In-House Legal Team of the Year for Intellectual Property Litigation by LMG Life Sciences
Nov 10, 2022 04:05PM Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Nov 10, 2022 04:05PM Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Nov 10, 2022 08:33AM Viatris Inc (VTRS) Wins Court Decision Invalidating AstraZeneca's (AZN) Symbicort Patent
Nov 10, 2022 08:30AM Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent
Nov 7, 2022 08:02AM Oyster Point Pharma Inc. (OYST) to be Acquired by Viatris (VTRS) for $11 Per Share Plus CVR
Nov 7, 2022 08:00AM Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
Nov 7, 2022 08:00AM Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event
Nov 7, 2022 08:00AM Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
Nov 7, 2022 06:50AM Viatris Reports Strong Third Quarter 2022 Results
Oct 24, 2022 04:30PM Viatris to Report Financial Results for the Third Quarter 2022 and Provide an Update on its February 28 Investor Event on November 7, 2022
Oct 11, 2022 02:15PM Viatris Named to Forbes' Annual List of the World's Best Employers for the Second Year in a Row
Sep 6, 2022 06:59AM Viatris Inc. to Participate in BofA Global Research Global Healthcare Conference
Aug 8, 2022 06:59AM Viatris Reports Strong Second Quarter 2022 Results
Jul 1, 2022 06:59AM Viatris Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022
May 20, 2022 05:30PM Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
May 16, 2022 06:59AM Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals
May 9, 2022 06:59AM Viatris Reports Strong First-Quarter 2022 Results
Apr 8, 2022 06:59AM Viatris Inc. to Release First Quarter 2022 Financial Results on May 9, 2022
Mar 30, 2022 09:00AM Sesame Workshop and Viatris Launch New Emotional Health and Wellbeing Resources for Families Grappling with Effects of COVID-19
Mar 17, 2022 02:55PM Viatris Inc (VTRS) Defeats Biogen's (BIIB) Attempt to Revive Tecfidera Patent
Mar 17, 2022 02:54PM Viatris Defeats Biogen's Attempt to Revive Tecfidera Patent
Mar 16, 2022 07:30AM Viatris Inc (VTRS) Receives FDA Approval for Generic Version of Symbicort Inhalation Aerosol
Mar 16, 2022 07:30AM Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partners
Mar 1, 2022 04:30PM Viatris to Participate in Upcoming Investor Conferences
View More Recent Stories View Older Stories